Galecto Inc (GLTO) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Galecto Inc (GLTO) has a cash flow conversion efficiency ratio of -0.040x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-20.60 Million) by net assets ($510.26 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see GLTO stock market capitalisation for the company's overall valuation and market capitalisation.
Galecto Inc - Cash Flow Conversion Efficiency Trend (2018–2025)
This chart illustrates how Galecto Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Galecto Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Galecto Inc ranked by their cash flow conversion efficiency. See how well can Galecto Inc service its debt to evaluate how effectively operating cash flow covers total debt obligations.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Aygaz AS
IS:AYGAZ
|
0.003x |
|
Aerospace Nanhu Electronic Information Technology Co. Ltd. A
SHG:688552
|
N/A |
|
Capital Southwest Corporation
NASDAQ:CSWC
|
-0.076x |
|
Chinese Universe Publishing And Media Co Ltd
SHG:600373
|
0.034x |
|
Wealthfront Corporation Common Stock
NASDAQ:WLTH
|
0.037x |
|
Deutsche EuroShop AG
F:DEQ
|
0.014x |
|
Lotus Pharmaceutical Co Ltd
TW:1795
|
0.029x |
|
Tong Yang Industry Co Ltd
TW:1319
|
0.079x |
Annual Cash Flow Conversion Efficiency for Galecto Inc (2018–2025)
The table below shows the annual cash flow conversion efficiency of Galecto Inc from 2018 to 2025. View Galecto Inc share price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $240.38 Million | $-6.73 Million | -0.028x | +97.62% |
| 2024-12-31 | $15.83 Million | $-18.62 Million | -1.176x | -3.04% |
| 2023-12-31 | $32.33 Million | $-36.91 Million | -1.142x | -64.22% |
| 2022-12-31 | $61.75 Million | $-42.93 Million | -0.695x | -55.80% |
| 2021-12-31 | $117.22 Million | $-52.31 Million | -0.446x | -93.30% |
| 2020-12-31 | $165.49 Million | $-38.20 Million | -0.231x | +42.10% |
| 2019-12-31 | $48.47 Million | $-19.33 Million | -0.399x | +10.71% |
| 2018-12-31 | $30.66 Million | $-13.69 Million | -0.447x | -- |
About Galecto Inc
Damora Therapeutics, Inc., a clinical-stage biotechnology company, develops molecule therapeutics for the treatment of fibrosis, cancer, inflammation, and other related diseases. It develops GB3226, a preclinical small molecule dual inhibitor of ENL-YEATS and FLT3 and GB1211, an oral small molecule inhibitor of galectin-3 to treat multiple types of oncology and liver disease indications. The comp… Read more